Amgen Joins AI/ML Gold Rush With Generate Deal
Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
More from AI
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.
More from Digital Technologies
Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma
MSD's chief information & digital officer emphasizes the need for pharma to accelerate technology adoption cycles to ensure drugs reach patients faster. The role of a robust digital backbone for seamless data flow, leadership commitment in digital transformation and an upcoming technology center in Hyderabad are other aspects he discussed.
CEOs of top Indian firms discuss how policies and geopolitics could shape future manufacturing networks and also the simmering issue of tariffs. US President Donald Trump has just reiterated plans for reciprocal tariffs at a joint session of Congress.